Evolus, Inc. (EOLS)
NASDAQ: EOLS · IEX Real-Time Price · USD
13.19
+0.57 (4.52%)
May 2, 2024, 3:29 PM EDT - Market open
Evolus Revenue
In the year 2023, Evolus had annual revenue of $202.09M with 35.98% growth. Revenue in the quarter ending December 31, 2023 was $61.00M with 39.76% year-over-year growth.
Revenue (ttm)
$202.09M
Revenue Growth
+35.98%
P/S Ratio
3.79
Revenue / Employee
$740,238
Employees
273
Market Cap
811.15M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 202.09M | 53.47M | 35.98% |
Dec 31, 2022 | 148.62M | 48.94M | 49.10% |
Dec 31, 2021 | 99.67M | 43.13M | 76.29% |
Dec 31, 2020 | 56.54M | 21.62M | 61.89% |
Dec 31, 2019 | 34.93M | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Healthcare Services Group | 1.68B |
HealthStream | 282.88M |
BioLife Solutions | 143.27M |
Sage Therapeutics | 91.06M |
Nurix Therapeutics | 80.89M |
Tango Therapeutics | 36.53M |
Mesoblast | 7.25M |
Pliant Therapeutics | 1.58M |
EOLS News
- 8 days ago - Evolus to Report First Quarter Financial Results on May 7, 2024 - Business Wire
- 14 days ago - Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau® - Business Wire
- 19 days ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference - Business Wire
- 7 weeks ago - Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock - Business Wire
- 7 weeks ago - Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance - Business Wire
- 2 months ago - Evolus Announces Results from European Head-to-Head Filler Trial - Business Wire
- 2 months ago - Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences - Business Wire